BioSpace News Archive

AVROBIO, Inc. announced that the company has granted non-statutory stock options for the purchase of up to an aggregate of 111,750 shares of the company’s common stock to eight new employees as inducement awards under the company’s 2019 Inducement Plan, in accordance with Nasdaq Listing Rule 5635.

Global Blood Therapeutics, Inc. announced that on April 1, 2020, the compensation committee of GBT’s board of directors granted three new employees restricted stock units for an aggregate of 10,550 shares of the company’s common stock.

Assure Holdings Corp., a provider of intraoperative neuromonitoring services, announced updates resulting from rapidly changing market conditions driven by the novel coronavirus pandemic.

resTORbio (Nasdaq: TORC) today announced that it will postpone enrollment in the fifth cohort of its ongoing Phase 1b/2a trial of RTB101, an orally administered, small molecule product candidate that is a potent inhibitor of target of rapamycin complex 1 (TORC1), alone or in combination with sirolimus, in Parkinson’s disease (PD).

VitalTech, a rapidly growing market leader in Virtual Care, announced today its partnership with VIVUS, Inc, a publicly held biopharmaceutical company (Nasdaq: VVUS). Leveraging VitalTech’s industry-leading virtual care platform and comprehensive medical device product line, VIVUS plans to rapidly accelerate the launch of its telemedicine, virtual care and remote patient monitoring capabilities

Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish fourth quarter and fiscal year 2020 financial results at 6:00 am EDT on Tuesday, May 5, 202

Cellect Biotechnology Ltd. (Nasdaq: APOP), a developer of a novel stem cell production technology, today announced operating and financial results for the fourth quarter and full year ended December 31, 2019.

In a letter sent to the leading trade organizations representing the nation’s hospitals and health systems, the National Kidney Foundation (NKF) expressed concern over news reports that some health systems and state governments are considering crisis-management policies which would deprive certain patient groups—including patients with end stage renal disease—of life-saving interventions for COVID-19

UroGen Pharma Ltd. (Nasdaq:URGN) announced positive interim data analysis of UGN-102 (mitomycin) for intravesical solution in patients with low-grade intermediate risk non-muscle invasive bladder cancer (LG IR-NMIBC)

venBio Partners LLC today announced the closing of venBio Global Strategic Fund III (“venBio Fund III”), its third life sciences venture capital fund, exceeding its target and closing on approximately $394 million in capital commitments in an oversubscribed fundraise.